Vascular surgeon's role in orthopedic surgery for muscle cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study examines the involvement of vascular surgeons in the surgical treatment of musculoskeletal tumors that affect vascular structures. It highlights the importance of vascular surgical assistance during orthopedic and spinal surgeries, which can significantly reduce intraoperative and postoperative complications. The study aims to gather data on cases where vascular intervention is necessary, focusing on the outcomes and safety of these procedures. By analyzing these cases, the study seeks to improve surgical strategies and patient care in the management of musculoskeletal tumors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient diagnosed with musculoskeletal tumor involving vascular structures requiring surgical removal
* Planned surgical treatment with intraoperative assistance of the vascular surgeon
* Obtaining informed consent
* Age 18 years

Exclusion Criteria:

\-

Where it's running

• IRCCS AOU di Bologna Policlinico di Sant'Orsola
  Bologna, Italia, Italy Recruiting

Study contacts

• Principal investigator: Mauro Gargiulo, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
• Study coordinator: Mauro Gargiulo, MD
• Email: mauro.gargiulo2@unibo.it
• Phone: 0512143288

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NMIBC sample collection to test cancer monitoring biomarkers

  This study tests a blood, urine, and tumor tissue collection approach in people with high-risk non-muscle invasive bladder cancer to see if a molecular test can detect residual disease and monitor recurrence.

  Recruiting Natera, Inc. · Austin, Texas · NCT07763197

• Sequential Gemcitabine Plus Docetaxel vs Gemcitabine Plus Mitomycin C for BCG-Unresponsive NMIBC

  This study tests whether adding docetaxel after gemcitabine is better or worse than adding mitomycin C after gemcitabine for people with BCG-unresponsive high-grade non-muscle-invasive bladder cancer.

  Recruiting Phase 2 Blokhin's Russian Cancer Research Center · Moscow, Moscow · NCT07747740

• Is ongoing systemic immunotherapy needed after achieving tumor-free status in very-high-risk NMIBC?

  This study tests whether patients who have become tumor-free after a systemic immunotherapy-based bladder-sparing treatment can safely stop therapy and instead be watched closely.

  Recruiting at 4 sites Phase 2 Tianjin Medical University Second Hospital · Tianjin and 3 other locations · NCT07625527

• Comparing CT and MRI with VI-RADS for Bladder Cancer Staging

  This study tests how well CT and MRI with VI-RADS can correctly stage bladder cancer before surgery in adults.

  Recruiting Oslo University Hospital · Oslo · NCT07602010

• How bladder microbes and immune signals affect lower urinary tract health

  This project will test whether differences in bladder microbes and immune signals are linked to urinary tract health in adults with and without various urinary conditions.

  Recruiting University of Zurich · Zurich, Canton of Zurich · NCT07494864

• Cretostimogene for BCG‑unresponsive high‑grade non‑muscle‑invasive bladder cancer

  This treatment will test cretostimogene plus n‑dodecyl‑β‑D‑maltoside in adults whose high‑grade non‑muscle‑invasive bladder cancer did not respond to BCG (carcinoma in situ with or without Ta/T1 tumors).

  Recruiting at 14 sites Phase 2 Lepu Biopharma Co., Ltd. · Beijing, Beijing Municipality and 13 other locations · NCT07283835

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.